Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GHSR | Q92847 | 3/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20207772 | 0.80 | PDE2A (0.52) | GHSRPTGDR2GAAPDE2AMAOB | |
| SCHEMBL6197245 | 0.79 | TSHR (0.50) | TSHRGHSRGAACTSKMAOB | |
| SCHEMBL6201447 | 0.78 | TSHR (0.48) | TSHRGHSRGAAPOLB | |
| SCHEMBL31194571 | 0.74 | TSHR (0.70) | TSHRGAAPOLB | |
| SCHEMBL3716061 | 0.74 | TSHR (0.43) | TSHRGHSRGAAPDE2ACTSK | |
| SCHEMBL20500103 | 0.71 | CTSL (0.41) | TSHRGHSRGAACTSK | |
| SCHEMBL20581457 | 0.69 | PDE2A (0.49) | PDE2A | |
| SCHEMBL7303767 | 0.69 | TSHR (1.00) | TSHRGAAPOLB | |
| SCHEMBL18282716 | 0.68 | PDE2A (0.71) | PDE2A | |
| SCHEMBL22475620 | 0.68 | MEN1 (0.39) | TSHRGHSRPTGDR2PDE2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3302486-B1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10174037-B2 | Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | TSHR 2910/4885GHSR 1735/4885PTGDR2 71/4885 |
| US-10174037-B2 | Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors | PDE12, PDE2A, PDE4D | TSHR 2910/4885GHSR 1735/4885PTGDR2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.